SLCO (and OATP) overexpression has already been shown to be an important factor in colon and prostate cancer (1,2); moreover variation in OATP function [1] appears to be related to clinical outcome of endocrine therapy in prostate cancer [5] as well as overall survival of men CRPC [1]. Here, SLCO1A2 is linked to prostate carcinoma.